Bioenvision to Hold Fiscal 2007 Year-End Financial Results Conference Call Wednesday, September 12, 2007.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Bioenvision, Inc. (Nasdaq:BIVN) will hold a live webcast of its quarterly conference call at 10:00 a.m. (EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) on Wednesday Wednesday: see week. , September September: see month. 12, 2007. Jim Scibetta, chief financial officer, will host the call. Senior management will discuss the Company's financial results and recent developments for the fiscal year ended June June: see month. 30, 2007. Bioenvision will announce the highlights of these topics in a press release to be issued before the market opens on September 12, 2007, prior to the conference call. The live conference call and webcast can be accessed with the following information. Live Toll Free Number (US & Canada): 866-585-6398 Live International Number: 416-849-9626 Webcast: www.bioenvision.com A replay of the call and webcast will be available for 14 days and can be accessed with the following information. Replay Toll Free Number (US & Canada): 866-245-6755 Replay International Number: 416-915-1035 Replay Passcode: 375872 Webcast Replay: www.bioenvision.com About Bioenvision Bioenvision's primary focus is the acquisition, development and marketing of compounds and technologies for the treatment of cancer. Bioenvision's product pipeline is focused on: Evoltra[R] and Modrenal[R]. For more information on Bioenvision please visit our website at www.bioenvision.com. Certain statements contained in this press release are "forward-looking for·ward-look·ing adj. Concerned with or making provision for the future: forward-looking educators; a forward-looking corporate plan. Adj. 1. " statements, including express or implied statements regarding Bioenvision obtaining regulatory approval of its products and Bioenvision's ability to deliver the additional data requested by the EMeA. Because these statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with whether the merger of Wichita Bio Corporation with and into Bioenvision will be approved by the stockholders of Bioenvision; risks associated with the uncertainty as to whether such merger will in fact occur, risks associated with disruptions from the proposed merger transaction which may harm relationships with customers, employees, suppliers and partners; risks associated with the outcome of litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and regulatory proceedings to which we are currently a party and may become a party in the future; risks associated with preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law and the statements contained in this press release are current as of the date of this release only. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion